ArticleVaccine2010
Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- Extended receptor repertoire of an adenovirus associated with human obesity.PLoS pathogens · 2025Article
- Identification and characterization of a novel human adenovirus type HAdV-D116.Frontiers in microbiology · 2025Article
- Comparative analysis of the impact of 40 adenovirus types on dendritic cell activation and CD8Frontiers in immunology · 2023Article
- Human species D adenovirus hexon capsid protein mediates cell entry through a direct interaction with CD46.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Species D Adenoviruses as Oncolytic Viral Vectors.Viruses · 2020Article
- Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines.Vaccines · 2020Review
- A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.PLoS neglected tropical diseases · 2020Article
- Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.Frontiers in immunology · 2020Review
- Boosting BCG with proteins or rAd5 does not enhance protection against tuberculosis in rhesus macaques.NPJ vaccines · 2019Article
- Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs.Vaccines · 2018Article
- Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.Virology · 2018Article
- The Journey ofFrontiers in immunology · 2018Review
- Review
- Native and engineered tropism of vectors derived from a rare species D adenovirus serotype 43.Oncotarget · 2016Article
- Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Review
- Article
- Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.The Journal of clinical investigation · 2015Article
- Progress on adenovirus-vectored universal influenza vaccines.Human vaccines & immunotherapeutics · 2015Review
- Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression.Vaccine · 2014Article
- Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Adenovirus vaccine vectors derived from rare human serotypes have been shown to be less potent than serotype 5 (Ad5) at inducing immune responses to encoded antigens. To identify highly immunogenic adenovirus vectors, we assessed pro-inflammatory cytokine expression, binding to the CD46 receptor, and immunogenicity. Species D adenoviruses uniquely suppressed pro-inflammatory cytokines and induced high levels of type I interferon. Thus, it was unexpected that a vector derived from a representative serotype, Ad28, induced significantly higher transgene-specific T cell responses than an Ad35 vector. Prime-boost regimens with Ad28, Ad35, Ad14, or Ad5 significantly boosted T cell and antibody responses. The seroprevalence of Ad28 was confirmed to be <10% in the United States. Together, this shows that a rare human serotype-based vector can elicit strong immune responses, which was not predicted by in vitro results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.